Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2010
12/23/2010US20100324146 Dendrimeric Enzyme Inhibitors
12/23/2010US20100324139 Process to pregabalin
12/23/2010US20100324118 Method for the Promotion of Angiogenesis, Vascularization, or Vascular Repair or for the Inhibition of Tumor Angiogenesis
12/23/2010US20100324114 Methods and kits to detect hereditary angioedema type III
12/23/2010US20100324108 Substituted isoindoline-1,3-dione derivatives
12/23/2010US20100324106 Compounds
12/23/2010US20100324105 Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids
12/23/2010US20100324104 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
12/23/2010US20100324093 Ccr9 inhibitors and methods of use thereof
12/23/2010US20100324084 Urea derivatives of tropane, their preparation and their therapeutic application
12/23/2010US20100324081 Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
12/23/2010US20100324076 Novel sEH Inhibitors and their Use
12/23/2010US20100324075 Therapeutic use of carboxyl ester lipase inhibitors
12/23/2010US20100324073 Pyrazolo [1,5-A] Pyrimidine Compounds
12/23/2010US20100324071 Novel glucokinase activators and methods of using same
12/23/2010US20100324070 Indole, indazole and benzimidazole arylamides as p2x3 and p2x2/3 antagonists
12/23/2010US20100324052 Novel piperidine carboxylic acid amine derivatives
12/23/2010US20100324043 Bicyclic And Tricyclic Compounds As KAT II Inhibitors
12/23/2010US20100324037 Pharmacokinetically improved compounds
12/23/2010US20100324036 Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
12/23/2010US20100324026 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
12/23/2010US20100324019 Use of Riboflavin in the Treatment of Hypertension
12/23/2010US20100324010 Amide compounds and use of the same
12/23/2010US20100324005 Method for treatment of diseases
12/23/2010US20100324003 Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders
12/23/2010US20100324001 Novel Methods for the Treatment of Inflammatory Diseases
12/23/2010US20100324000 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta2 adrenergic receptors
12/23/2010US20100323999 Therapeutic Molecules and Methods-1
12/23/2010US20100323991 Methods and products for treatment of diseases
12/23/2010US20100323986 Compositions and methods for modulation of vascular structure and/or function
12/23/2010US20100323981 Treatment of statin side effects
12/23/2010US20100323975 Therapeutic agent for cerebral ischemic injury
12/23/2010US20100323974 Inhibitors of PARP Activity and Uses Thereof
12/23/2010US20100323956 Glucose-regulating polypeptides and methods of making and using same
12/23/2010US20100323950 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
12/23/2010US20100323039 Labisia pumila extracts for reducing the risk of cardiovascular diseases
12/23/2010US20100323029 Five-coordinate neuroglobin and use thereof as a blood substitute
12/23/2010US20100323028 Method and composition for treating pulmonary hemorrhage
12/23/2010US20100323027 Mesenchymal stem cell conditioned medium
12/23/2010US20100323026 Sustained release preparation for tissue regeneration therapy
12/23/2010US20100323012 Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and Diuretics
12/23/2010US20100323010 Formulation and process for drug loaded cores
12/23/2010US20100322998 Skin ulcer preventive curative agent containing human recombinant hgf
12/23/2010US20100322992 Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device
12/23/2010US20100322989 Hydrophilic skin cleaning cloth
12/23/2010US20100322960 Ganoderma tsugae Active Substance Having Endothelial Cell-protecting and Atherosclerosis-preventing Effects, Process for Preparing the Same and Composition Containing the Same
12/23/2010US20100322948 Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of same
12/23/2010US20100322930 Fibronectin-based binding molecules and their use
12/23/2010US20100322921 METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF
12/23/2010US20100322918 Diffusion enhancing compounds and their use alone or with thrombolytics
12/23/2010US20100322870 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
12/23/2010US20100322869 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
12/23/2010US20100322856 Compositions and Methods for Inducing Angiogenesis
12/23/2010US20100322853 Nanoparticulate compositions of angiogenesis inhibitors
12/23/2010US20100322852 Nanoparticulate compositions of angiogenesis inhibitors
12/23/2010CA2764124A1 Substituted isoquinoline derivative
12/22/2010EP2264175A1 Fibroblast growth factor homologs
12/22/2010EP2264173A2 Use of a double-stranded ribonucleic acid for targeted inhibition of the expression of a given target gene
12/22/2010EP2264073A1 Endothelial cell specific antibodies and uses thereof
12/22/2010EP2264059A1 Polypeptides, cDNAs encoding the same and utilization thereof
12/22/2010EP2264029A1 1,3-dihydroisobenzofuran derivative
12/22/2010EP2264028A1 Pyrazole compounds useful as protein kinase inhibitors
12/22/2010EP2263697A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
12/22/2010EP2263695A2 Method and preparation for treating depressions
12/22/2010EP2263670A1 Use of angiotensin II receptor antagonists in order to increase insulin sensitivity
12/22/2010EP2263652A1 Aerosols comprising nanoparticle drugs
12/22/2010EP2262786A2 Colchicine solid-state forms; methods of making; and methods of use thereof
12/22/2010EP2262778A2 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
12/22/2010EP2262777A2 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cri
12/22/2010EP2262525A1 Apoaequorin-containing compositions and methods of using same
12/22/2010EP2262524A2 Compositions and methods for treating pathologic angiogenesis and vascular permeability
12/22/2010EP2262518A1 Extract from oil palm leaves comprising phenolic acids
12/22/2010EP2262514A1 Agents for promoting secretion and/or suppressing decrease of adiponectin
12/22/2010EP2262500A1 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
12/22/2010EP2041100B1 Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
12/22/2010EP1984002B1 Trialkylsilylbenzylaminocarboxyindoles, indazoles and indolines and their use in treating cetp-mediated disorders
12/22/2010EP1412317B1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities
12/22/2010EP1364660B1 Drug-releasing system of biodegradable polymer type
12/22/2010CN1973681B Technological process of producing oat diet fiber and nutritious powder with oat bran
12/22/2010CN1826122B Oxidized phospholipids and application in atherosclerosis treatment thereof
12/22/2010CN1812973B Indazole compounds useful as protein kinase inhibitors
12/22/2010CN1662242B Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/22/2010CN1626133B Medication for treating coronary heart disease
12/22/2010CN1547477B Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
12/22/2010CN101925601A Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and pharmaceutical composition comprising it - 026
12/22/2010CN101925362A Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor
12/22/2010CN101921772A Human antibodies that bind human IL-12 and methods for producing
12/22/2010CN101921282A 7,2'-dehydration puerarin, salt derivatives as well as preparation method and application thereof
12/22/2010CN101921279A Spirocyclic heterocyclic derivatives and methods of their use
12/22/2010CN101921270A Mangiferin berberine salt, preparation method thereof and use thereof
12/22/2010CN101921267A Beta -lactamyl vasopressin Vla antagonists
12/22/2010CN101921265A Biphenylacylamine tetrazole compounds, synthetic method and application
12/22/2010CN101921264A Candesartan organic amine salt and preparation method and application thereof
12/22/2010CN101921247A 1-(cinnamoyl)-4-piperidyl amide piperazidine compound and preparation method thereof
12/22/2010CN101921238A Preparation of substituted nitrogen-containing benzoheterocycle derivatives and pharmacological application thereof
12/22/2010CN101921225A Pirfenidone compound, preparation method and application thereof
12/22/2010CN101920019A Hydrophilic polymer-puerarin specific conjugated non-hemolytic conjugate
12/22/2010CN101919992A Preparation utilizing Chinese herbal medicines to reduce human body platelet filtration serum dirt and prevent and cure cerebral hemorrhage
12/22/2010CN101919990A Traditional Chinese medicine preparation for treating hemiplegia caused by apoplexy
12/22/2010CN101919971A Agent for locally preventing and treating body surface diseases